Research

Publications

Below you can find a list of our published research.

6205 results

Cited 61 times since 2014 (5.7 per year) source: EuropePMC

FASEB journal : official publication of the Federation of American Societies for Experimental Biology, Volume 28, Issue 12, 25 4 2014, Pages 5361-5375 Peripheral cannabinoid 1 receptor blockade activates brown adipose tissue and diminishes dyslipidemia and obesity. Boon MR, Kooijman S, van Dam AD, Pelgrom LR, Berbée JF, Visseren CA, van Aggele RC, van den Hoek AM, Sips HC, Lombès M, Havekes LM, Tamsma JT, Guigas B, Meijer OC, Jukema JW, Rensen PC

The endocannabinoid system is an important player in energy metabolism by regulating appetite, lipolysis, and energy expenditure. Chronic blockade of the cannabinoid 1 receptor (CB1R) leads to long-term maintenance of weight loss and reduction of dyslipidemia in experimental and human obesity. The molecular mechanism by which CB1R blockade reverses dyslipidemia in obesity has not yet been clarified. In this study, we showed that CB1R blockade with the systemic CB1R blocker rimonabant enhanced wh... Abstract

Cited 31 times since 2014 (2.9 per year) source: EuropePMC

Circulation. Arrhythmia and electrophysiology, Volume 7, Issue 5, 23 4 2014, Pages 889-897 Left-sided ablation of ventricular tachycardia in adults with repaired tetralogy of Fallot: a case series. Kapel GF, Reichlin T, Wijnmaalen AP, Tedrow UB, Piers SR, Schalij MJ, Hazekamp MG, Jongbloed MR, Stevenson WG, Zeppenfeld K

Background: Radiofrequency catheter ablation (RFCA) of ventricular tachycardia (VT) in repaired Tetralogy of Fallot focuses on isthmuses in the right ventricle but may be hampered by hypertrophied myocardium or prosthetic material. These patients may benefit from ablation at the left side of the ventricular septum. Methods and results: Records from 28 consecutive repaired Tetralogy of Fallot patients from 2 centers who underwent VT ablation were reviewed. Ablation targeted anatomic isthmuses con... Abstract

Cited 8 times since 2014 (0.7 per year) source: EuropePMC

Cardiovascular and interventional radiology, Volume 38, Issue 3, 22 4 2014, Pages 600-605 Thromboembolic complications after Zenith® Low Profile Endovascular Graft for infrarenal abdominal aneurysms. Urlings TA, de Vries AC, de Mol van Otterloo JC, Eefting D, van der Linden E

Purpose: The purpose of this study was to objectify and evaluate risk factors for thromboembolic complications after treatment with a Zenith(®) Low Profile Endovascular Graft (Zenith LP). Results were compared with those in the recent literature on endovascular aortic repair (EVAR) and with the thromboembolic complications in the patient group treated with a Zenith Flex Endovascular Graft in our institute in the period before the use of the Zenith LP. Materials and methods: All consecutive patie... Abstract

Cited 29 times since 2014 (2.7 per year) source: EuropePMC

Journal of magnetic resonance imaging : JMRI, Volume 41, Issue 6, 20 3 2014, Pages 1512-1520 Characterization and improved quantification of left ventricular inflow using streamline visualization with 4DFlow MRI in healthy controls and patients after atrioventricular septal defect correction. Calkoen EE, Roest AA, Kroft LJ, van der Geest RJ, Jongbloed MR, van den Boogaard PJ, Blom NA, Hazekamp MG, de Roos A, Westenberg JJ

Purpose: To evaluate trans-left atrioventricular valve (LAVV) blood flow and optimize left ventricular inflow quantification in healthy controls and patients after atrioventricular septal defect (AVSD) correction. Materials and methods: Twenty-five patients after AVSD correction and 25 controls underwent 4DFlow MRI. Using streamline visualization in four- and two-chamber views, inflow direction at early and late filling was defined at the annulus level and at the peak inflow velocity (PIV) level... Abstract

Cited 54 times since 2014 (5 per year) source: EuropePMC

European heart journal, Volume 36, Issue 1, 20 3 2014, Pages 39-48 Anacetrapib reduces progression of atherosclerosis, mainly by reducing non-HDL-cholesterol, improves lesion stability and adds to the beneficial effects of atorvastatin. Kühnast S, van der Tuin SJ, van der Hoorn JW, van Klinken JB, Simic B, Pieterman E, Havekes LM, Landmesser U, Lüscher TF, Willems van Dijk K, Rensen PC, Jukema JW, Princen HM

Background: The residual risk that remains after statin treatment supports the addition of other LDL-C-lowering agents and has stimulated the search for secondary treatment targets. Epidemiological studies propose HDL-C as a possible candidate. Cholesteryl ester transfer protein (CETP) transfers cholesteryl esters from atheroprotective HDL to atherogenic (V)LDL. The CETP inhibitor anacetrapib decreases (V)LDL-C by ∼15-40% and increases HDL-C by ∼40-140% in clinical trials. We evaluated the effec... Abstract

Cited 133 times since 2014 (12.3 per year) source: EuropePMC

Journal of lipid research, Volume 55, Issue 10, 19 3 2014, Pages 2103-2112 Alirocumab inhibits atherosclerosis, improves the plaque morphology, and enhances the effects of a statin. Kühnast S, van der Hoorn JW, Pieterman EJ, van den Hoek AM, Sasiela WJ, Gusarova V, Peyman A, Schäfer HL, Schwahn U, Jukema JW, Princen HM

Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibition is a potential novel strategy for treatment of CVD. Alirocumab is a fully human PCSK9 monoclonal antibody in phase 3 clinical development. We evaluated the antiatherogenic potential of alirocumab in APOE*3Leiden.CETP mice. Mice received a Western-type diet and were treated with alirocumab (3 or 10 mg/kg, weekly subcutaneous dosing) alone and in combination with atorvastatin (3.6 mg/kg/d) for 18 weeks. Alirocumab alone dose-dependen... Abstract

European heart journal. Cardiovascular Imaging, Volume 15, Issue 12, 19 3 2014, Pages 1428 Three-dimensional transoesophageal echocardiographic visualization of malignant anomalous left main coronary origin and course causing sudden cardiac death. Kamperidis V, Katsanos S, Bertels RA, Schalij MJ, Delgado V

Abstract

Cited 21 times since 2014 (1.9 per year) source: EuropePMC

European journal of heart failure, Volume 16, Issue 10, 19 3 2014, Pages 1104-1111 Super-responders to cardiac resynchronization therapy remain at risk for ventricular arrhythmias and benefit from defibrillator treatment. van der Heijden AC, Höke U, Thijssen J, Borleffs CJ, van Rees JB, van der Velde ET, Schalij MJ, van Erven L

Aims: Mortality and ventricular arrhythmias are reduced in patients responding to cardiac resynchronization therapy (CRT). This response is accompanied by improvement in LVEF, and some patients even outgrow original eligibility criteria for implantable cardioverter-defibrillator (ICD) implantation. It is however unclear if these patients still benefit from ICD treatment. The current study aimed to evaluate if the incidence of ICD therapy is related to the extent of CRT response. Methods and resu... Abstract

Cited 20 times since 2014 (1.9 per year) source: EuropePMC

The Annals of thoracic surgery, Volume 98, Issue 5, 19 3 2014, Pages 1680-1686 More than 25 years of experience in managing pulmonary atresia with intact ventricular septum. Schneider AW, Blom NA, Bruggemans EF, Hazekamp MG

Background: Management of pulmonary atresia with intact ventricular septum (PAIVS) is challenging and depends on the individual patient's morphologic characteristics. We evaluated outcomes of 25 years of experience in morphologically driven management of PAIVS. Methods: Between January 1985 and December 2011, 60 patients were treated for PAIVS. Patients were retrospectively categorized into mild (n=27), moderate (n=18), and severe (n=15) right ventricular (RV) hypoplasia subgroups based on... Abstract

Cited 20 times since 2014 (1.9 per year) source: EuropePMC

International journal of cardiology, Volume 176, Issue 3, 17 3 2014, Pages 776-781 Increased carotid intima-media thickness predicts cardiovascular events in aortic coarctation. Luijendijk P, Lu H, Heynneman FB, Huijgen R, de Groot EE, Vriend JW, Vliegen HW, Groenink M, Bouma BJ, Mulder BJ

Background: Adult post-coarctectomy patients (CoA) demonstrate increased cardiovascular morbidity and mortality. The carotid intima-media thickness (CIMT), a marker for atherosclerosis, is increased in CoA. The aim was to evaluate the predictive value of CIMT for cardiovascular events. Methods and results: Consecutive CoA patients were prospectively studied during 10.1±0.7 years follow-up. At baseline and follow-up echocardiography, MRI imaging and CIMT imaging were performed, while cardiovascul... Abstract

Cited 4 times since 2014 (0.4 per year) source: Scopus

The international journal of cardiovascular imaging, Volume 31, Issue 1, 17 3 2014, Pages 37-43 Pericardial effusion following transcatheter aortic valve implantation: echocardiography and multi-detector row computed tomography evaluation. Katsanos S, van Rosendael P, Kamperidis V, van der Kley F, Regeer M, Al-Amri I, Karalis I, Palmen M, de Weger A, Marsan NA, Bax JJ, Delgado V

Although pericardial effusion (PE) early after transcatheter aortic valve implantation (TAVI) has been reported in few registries, late PE at follow-up remains unexplored. Particularly, after transapical TAVI, diagnosis of PE with transthoracic echocardiography (TTE) may be challenging. The present evaluation assessed the incidence of PE early after TAVI and at 1 month follow-up using TTE and multi-detector computed tomography (MDCT). The agreement between TTE and MDCT to diagnose the presence a... Abstract

Cited 34 times since 2014 (3.2 per year) source: EuropePMC

Journal of cellular and molecular medicine, Volume 18, Issue 10, 15 3 2014, Pages 2020-2030 Complement factor C5a induces atherosclerotic plaque disruptions. Wezel A, de Vries MR, Lagraauw HM, Foks AC, Kuiper J, Quax PH, Bot I

Complement factor C5a and its receptor C5aR are expressed in vulnerable atherosclerotic plaques; however, a causal relation between C5a and plaque rupture has not been established yet. Accelerated atherosclerosis was induced by placing vein grafts in male apoE(-/-) mice. After 24 days, when advanced plaques had developed, C5a or PBS was applied locally at the lesion site in a pluronic gel. Three days later mice were killed to examine the acute effect of C5a on late stage atherosclerosis. A signi... Abstract

Cited 138 times since 2014 (12.8 per year) source: EuropePMC

Circulation, Volume 130, Issue 15, 14 2 2014, Pages 1225-1235 Integrating genetic, transcriptional, and functional analyses to identify 5 novel genes for atrial fibrillation. Sinner MF, Tucker NR, Lunetta KL, Ozaki K, Smith JG, Trompet S, Bis JC, Lin H, Chung MK, Nielsen JB, Lubitz SA, Krijthe BP, Magnani JW, Ye J, Gollob MH, Tsunoda T, Müller-Nurasyid M, Lichtner P, Peters A, Dolmatova E, Kubo M, Smith JD, Psaty BM, Smith NL, Jukema JW, Chasman DI, Albert CM, Ebana Y, Furukawa T, Macfarlane PW, Harris TB, Darbar D, Dörr M, Holst AG, Svendsen JH, Hofman A, Uitterlinden AG, Gudnason V, Isobe M, Malik R, Dichgans M, Rosand J, Van Wagoner DR, METASTROKE Consortium, AFGen Consortium, Benjamin EJ, Milan DJ, Melander O, Heckbert SR, Ford I, Liu Y, Barnard J, Olesen MS, Stricker BH, Tanaka T, Kääb S, Ellinor PT

Background: Atrial fibrillation (AF) affects >30 million individuals worldwide and is associated with an increased risk of stroke, heart failure, and death. AF is highly heritable, yet the genetic basis for the arrhythmia remains incompletely understood. Methods and results: To identify new AF-related genes, we used a multifaceted approach, combining large-scale genotyping in 2 ethnically distinct populations, cis-eQTL (expression quantitative trait loci) mapping, and functional validation. F... Abstract

Cited 7 times since 2014 (0.6 per year) source: EuropePMC

PloS one, Volume 9, Issue 8, 14 2 2014, Pages e105019 Increased platelet reactivity is associated with circulating platelet-monocyte complexes and macrophages in human atherosclerotic plaques. Rutten B, Tersteeg C, Vrijenhoek JE, van Holten TC, Elsenberg EH, Mak-Nienhuis EM, de Borst GJ, Jukema JW, Pijls NH, Waltenberger J, van Zonneveld AJ, Moll FL, McClellan E, Stubbs A, Pasterkamp G, Hoefer I, de Groot PG, Roest M

Objective: Platelet reactivity, platelet binding to monocytes and monocyte infiltration play a detrimental role in atherosclerotic plaque progression. We investigated whether platelet reactivity was associated with levels of circulating platelet-monocyte complexes (PMCs) and macrophages in human atherosclerotic carotid plaques. Methods: Platelet reactivity was determined by measuring platelet P-selectin expression after platelet stimulation with increasing concentrations of adenosine diphosphate... Abstract

Cited 1 times since 2014 (0.1 per year) source: EuropePMC

Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology, Volume 21, Issue 6, 12 2 2014, Pages 1072-1074 The potential role of gated myocardial perfusion SPECT imaging in patient selection for cardiac resynchronization therapy. Marsan NA, Bax JJ

Abstract

Cited 34 times since 2014 (3.1 per year) source: EuropePMC

Journal of surgical oncology, Volume 110, Issue 7, 11 2 2014, Pages 845-850 Optimization of sentinel lymph node mapping in bladder cancer using near-infrared fluorescence imaging. Schaafsma BE, Verbeek FP, Elzevier HW, Tummers QR, van der Vorst JR, Frangioni JV, van de Velde CJ, Pelger RC, Vahrmeijer AL

Background and objectives: Unlike other cancers, the Sentinel Lymph Node (SLN) procedure in bladder cancer requires special attention to the injection technique. The aim of this study was to assess feasibility and to optimize tracer injection technique for SLN mapping in bladder cancer patients using NIR fluorescence imaging. Methods: Twenty patients with invasive bladder cancer scheduled for radical cystectomy were prospectively enrolled. Indocyanine green (ICG) bound to human serum albumin (co... Abstract

Cited 58 times since 2014 (5.4 per year) source: EuropePMC

International journal of cancer, Volume 136, Issue 6, 8 2 2014, Pages 1434-1444 Sorafenib synergizes with metformin in NSCLC through AMPK pathway activation. Groenendijk FH, Mellema WW, van der Burg E, Schut E, Hauptmann M, Horlings HM, Willems SM, van den Heuvel MM, Jonkers J, Smit EF, Bernards R

The multikinase inhibitor sorafenib is under clinical investigation for the treatment of many solid tumors, but in most cases, the molecular target responsible for the clinical effect is unknown. Furthermore, enhancing the effectiveness of sorafenib using combination strategies is a major clinical challenge. Here, we identify sorafenib as an activator of AMP-activated protein kinase (AMPK), in a manner that involves either upstream LKB1 or CAMKK2. We further show in a phase II clinical trial in... Abstract

Cited 246 times since 2014 (22.8 per year) source: EuropePMC

American heart journal, Volume 168, Issue 5, 7 1 2014, Pages 682-689 Effect of alirocumab, a monoclonal antibody to PCSK9, on long-term cardiovascular outcomes following acute coronary syndromes: rationale and design of the ODYSSEY outcomes trial. Schwartz GG, Bessac L, Berdan LG, Bhatt DL, Bittner V, Diaz R, Goodman SG, Hanotin C, Harrington RA, Jukema JW, Mahaffey KW, Moryusef A, Pordy R, Roe MT, Rorick T, Sasiela WJ, Shirodaria C, Szarek M, Tamby JF, Tricoci P, White H, Zeiher A, Steg PG

Background: Following acute coronary syndrome (ACS), the risk for future cardiovascular events is high and is related to levels of low-density lipoprotein cholesterol (LDL-C) even within the setting of intensive statin treatment. Proprotein convertase subtilisin/kexin type 9 (PCSK9) regulates LDL receptor expression and circulating levels of LDL-C. Antibodies to PCSK9 can produce substantial and sustained reductions of LDL-C. The ODYSSEY Outcomes trial tests the hypothesis that treatment with al... Abstract

Revista espanola de cardiologia (English ed.), Volume 67, Issue 10, 4 1 2014, Pages 855-857 Value of intraoperative electrical parameters obtained during implantation of cardiac resynchronization therapy devices for the prediction of reverse remodeling. de Riva-Silva M, López-Gil M, Salgado-Aranda R, Fontenla-Cerezuela A, Salguero-Bodes R, Arribas-Ynsaurriaga F

Abstract

Cited 15 times since 2014 (1.4 per year) source: EuropePMC

International journal of cardiology, Volume 176, Issue 3, 3 1 2014, Pages 788-793 RP105 deficiency aggravates cardiac dysfunction after myocardial infarction in mice. Louwe MC, Karper JC, de Vries MR, Nossent AY, Bastiaansen AJ, van der Hoorn JW, Willems van Dijk K, Rensen PC, Steendijk P, Smit JW, Quax PH

Background: Toll-like receptor-4 (TLR4), a receptor of the innate immune system, is suggested to have detrimental effects on cardiac function after myocardial infarction (MI). RP105 (CD180) is a TLR4 homolog lacking the intracellular signaling domain that competitively inhibits TLR4-signaling. Thus, we hypothesized that RP105 deficiency, by amplifying TLR4 signaling, would lead to aggravated cardiac dysfunction after MI. Methods and results: First, whole blood from RP105-/- and wild-type (WT) ma... Abstract